and strategic reliability aspirin. system Thank ensure absorption year, our Vazalore consumers our reliable remain profile trade efficacy, within presence ensuring In leading unique safety launch innovative technology more community, inhibition and focused we scientific platelet well on communicated. of increasing that you, this Vazalore, to the of is retail with an very Rita. important the Vazalore’s that proprietary up to the is utilizes safe delivery fast, and
disease than suffer coronary studies patient times carotid clinical previous which event including up and they’ve ASCVD, for had lower artery attack that response or operation. aspirin, aspirin times have five known platelet aspirin, operation every regular better as absorption stroke achieves with with such heart ASCVD, or procedure vascular disease, recommendation than the than cardiovascular Our and vascular disease, coated XX% patients coated by two atherosclerotic possible therapy risk placement, guideline. to such aspirin. are Lifetime of as every or artery a Vazalore ulcers clinical by shown disease, disease vascular supported from Class Ia a or a previous a Roughly meaning Americans million bypass peripheral cerebrovascular is highest XX stent higher
who with vascular who currently don’t disease million a as In but should the are same for patient aspirin ASCVD, are have therapy. about there candidates be considered with and, patients addition, risk therefore, diabetes XX at
well To share highlighted billion. faster, would reliable This of total would revenue. than aspirin Taken stroke. focus important approximately market patients Vazalore a significantly and generate XX a prescribing together, upon $XX a of differentiated addressable even by risk you will Vazalore of and for therapy professionals or Accordingly, their our their on the heart the is of in an the on maintenance setting acute patients for acute an healthcare hospital from to G.I. of patients. this market absorption retail small over a is attack profile event clinical coated aspirin toxicity treatment suffering patients Vazalore discharge. equate to a of Vazalore’s strategy suited a perspective, part lower market transition the large million chronic more for significant for give
professionals, healthcare and to engage in consumers trade. the is important leaders groups; three mission retail Our with
This advances brand of among actively science kind Scientific continue important are XX,XXX care cardiology Expo solutions U.S. awareness College these constituents. participate to In XXth the of in exhibited nearly major American and in cardiovascular March, Cardiology’s to health raise and and in the Annual is that familiarity professionals. We latest Session gathering the where at by was conferences build the attended shared. largest and its we
American specializes recently professionals renowned Mark the Dr. just neurology are care and of stroke Neurology scientific intervention, Academy as Board. our neurologist Conference, also the PLx in largest Alberts, who one back We to advisory from gatherings of of welcomed
we with this cardiology, As leaders discussions our in event especially beyond exciting. specialties and was thought premier participating broaden
have attack, for response encouraged Neurologists at TIA, patients. for a very the and or a want transient risk from patients had who treat a need better a these Vazalore We’re ischemic having innovative aspirin by or stroke. and to neurologists new who
abstracts research. presenting proposition week, ISPOR value be for and on conference economics health global outcomes the Vazalore’s Next leading we’ll at two Conference,
advocacy retail build attended to key these As has with National discuss in leaders. Vazalore, a prestigious efforts life that seen Chain Annual Vazalore to gathering of to for We the over-the-counter potential Stores, NACDS part decades. Drug Conference, we of retailers category the innovation its an to Association no of met add and recently influential
innovative best Vazalore has alternative believe to market now We and that cause to at an by likely discuss meetings effective into the physicians We pharmacy. to promote less G.I. are therapies the how progressing Vazalore more aspirin today’s to planning and shelf potential to is and offering at consumers disrupt upset.
APIs. proprietary enables drug mechanism superior system novel action and life a multiple risk delivery strong patent offers benefit from Our targeted profile the of
As transform for our prospects of to questions. out current secondary toward of of regulatory go at we commercialization care I’d instructions. excited next With ahead Operator, advance very year, about in prevention the and like submission we’re middle in with the year our to that, the open this call end standard the market. please to the the
